European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision

Peter Y. K. van den Bergh, Robert D. M. Hadden, Pierre Bouche, David R. Cornblath, Angelika Hahn, Isabel Illa, Carol L. Koski, Jean-Marc Leger, Eduardo Nobile-Orazio, John Pollard, Claudia Sommer, Pieter A. van Doorn, Ivo N. van Schaik

Research output: Contribution to journalArticleAcademicpeer-review

465 Citations (Scopus)

Abstract

Recommendations: The Task Force agreed on Good Practice Points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were: (i) intravenous immunoglobulin (IVIg) (Recommendation Level A) or corticosteroids (Recommendation Level C) should be considered in sensory and motor CIDP; (ii) IVIg should be considered as the initial treatment in pure motor CIDP (Good Practice Point); (iii) if IVIg and corticosteroids are ineffective, plasma exchange (PE) should be considered (Recommendation Level A); (iv) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (Good Practice Point); (v) symptomatic treatment and multidisciplinary management should be considered (Good Practice Point)
Original languageEnglish
Pages (from-to)1-9
JournalJournal of the peripheral nervous system
Volume15
Issue number1
Publication statusPublished - 2010

Cite this